Monoclonal Anti-CD25 PE-Cyanine7 produced in mouse

The antibody MEM-181 reacts with an extracellular epitope of CD25 (Interleukin-2 receptor alpha chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.

CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R). Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.

PHA-activated peripheral blood leucocytes

The antibody solution should be gently mixed before use.

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-cyanine 7 (PE-Cy7) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.